Surgery in reference centers improves survival of sarcoma patients: a nationwide study


1Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; 2Université Claude Bernard, Lyon; 3Institut de Cancérologie L. Neuwirth; 4Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus—Surgery, Villejuif; 5Department of Medical Oncology and Department of Surgical Oncology, Institut Bergonie, Bordeaux; 6Department of Medical Oncology and Department of Surgical Oncology, Centre Oscar Lambret, Lille; 7Department of Surgical Oncology, CHU, Lille; 8Department of Medical Oncology and Department of Surgical Oncology, Institut de Cancérologie Nantes, Nantes; 9Department of Orthopedics, CHU Nantes, Nantes; 10Department of Orthopedics, Hôpital Cochin-Saint-Vincent de Paul, Paris; 11Department of Medical Oncology and Department of Orthopedics, Institut Universitaire de Cancérologie de Toulouse, Claudius Regaud, Toulouse; 12Department of Medical Oncology and Department of Orthopedics, La Timone University Hospital, Marseille; 13Medical Oncology Department, Eugene Marquis Comprehensive Cancer Center, Rennes; 14Department of Orthopedics, CHU, Rennes; 15Medical Oncology Department, Institut de Cancérologie de Montpellier, Montpellier; 16Department of Medical Oncology and Department of Surgical Oncology, Centre Alexis Vautrin, Vandoeuvre-les-Nancy; 17Department of Surgical Oncology and Department of Medical Oncology, Centre Paul Strauss & CHU Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg; 18Department of Orthopedics, CHU de Tours, Tours; 19Department of Medical Oncology and Department of Surgical Oncology, Institut Paoli Calmettes, Marseille; 20Department of Medical Oncology and Department of Surgical Oncology, Centre Antoine Lacassagne, Nice; 21Oncology Unit, Saint Louis Hospital, Paris; 22Department of Surgery, Centre Georges François Leclerc, Dijon; 23Department of Surgery, Centre Jean Perrin/ERTICA EA 4677, Clermont-Ferrand; 24Department of Medical Oncology and Department of Surgical Oncology, CHU Limoges, Limoges; 25Medical Oncology Department, CHU Besançon, Besançon; 26Department of Medical Oncology and Department of Surgical Oncology, Institut J Godinot Reims; 27Department of Surgical Oncology, Centre Francois Baclesse, Caen; 28Department of Surgery, Centre Henri Becquerel, Rouen; 29Medical Oncology Department, APHP La Pitié Salpêtrière/Tenon/Bicêtre, Paris; 30Medical Oncology Department, CHU La Réunion, Saint-Pierre, La Réunion; 31Surgery Department, Institut Curie, Paris, France

*Correspondence to: Prof. Jean-Yves Blay, Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, 28 rue Laennec, 69373 Lyon Cedex 08, France. Tel: +33-4-78-78-51-26; E-mail: jean-yves.blay@lyon.unicancer.fr

The members are listed in the supplementary document S1 (available at Annals of Oncology online).

Background: NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry.

Patients and methods: Patients’ characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497).

Results: Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li–Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and...
event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618–0.749) for OS].

**Conclusion:** This nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.

**Key words:** sarcoma, resection, surgery, relapse, survival, reference center

### Introduction

Sarcomas are a heterogeneous group of rare connective tissue cancers, with variable clinical presentations, and an estimated incidence close to 6.2/100 000/year [1–4]. In all clinical practice guidelines, it is recommended that the management of sarcoma patients should be carried out by a dedicated multidisciplinary team, including expert pathologists and surgeons, treating a large number of patients [5–7]. Because of their rarity, sarcoma is often initially misrecognized, misdiagnosed, and as a consequence not treated according to clinical practice guidelines [5–9]. Inadequate diagnostic procedure and treatment, e.g. enucleation of the tumor as initial surgery without initial imaging or biopsy, are observed in a large fraction of patients and often qualified as ‘whoops’ procedures [10–12]. We recently reported that presentation to a specialized multidisciplinary tumor board (MDTB) was independently correlated to reduction in the risk of relapse in a nationwide study involving the NETSARC Network [12]. Similar observations were reported by several other national initiatives [13–15].

Optimal surgical removal of sarcoma, with en bloc macroscopic resection and histological clear margins is the mainstay of the curative treatment of localized soft tissue sarcoma (STS) [5–9]. This quality of initial surgery is a major prognostic factor for recurrence-free survival and overall survival (OS) in all series [16–21].

In most European (and actually worldwide) countries, including France, the treatment of patients with sarcoma can be carried out primary care oncology hospital or clinic, with no specific guidance on the nature of the required multidisciplinary team or on number of patients treated. Conversely in Scandinavian countries as well as in the UK the management of sarcoma patients must be carried out in dedicated reference centers or on number of patients treated. The network for sarcoma (called NETSARC) in 2009, to improve the management and outcome of sarcoma patients. Twenty-six reference centers throughout the nation were identified. A Network for expert pathology diagnosis in sarcoma (RRePS) gathering 23 reference centers for pathology in charge of the second histological review for each suspected case was also created. A common database (netsarc.org) gathering all cases of sarcoma presented to MDTB was created and implemented, collected data on the diagnostic, therapeutic management, and the clinical outcome in terms of relapse and survival.

From 1 January 2010 to 1 May 2018, this database prospectively included a 47 023 patient population with 35 784 patients with sarcoma or tumor of intermediate malignancy. 11 239 (24%) patients in the database discussed in a NETSARC MDTB had a diagnosis which was not that of a sarcoma (benign tumor, e.g. lipoma, carcinoma, lymphoma, etc.).

The aim of the present study was to evaluate (i) the impact of predisposing conditions and patient history and (ii) the impact of surgery carried out in a NETSARC reference center on relapse and survival in the population of patients included in the NETSARC database.

### Patients and methods

#### The network

Each NETSARC center organizes an MDTB gathering sarcoma specialized pathologist(s), radiologist(s), surgeon(s), radiation oncologist(s), medical oncologist(s), and often molecular biologist(s), orthopedist(s), and pediatrician(s). All sarcoma or suspected sarcoma patient cases presented to the MDTB of all 26 centers were recorded in the database, by a dedicated team of Clinical research assistant, supervised by three coordinating centers (Centre Leon Bérard, Gustave Roussy, Institut Bergonie). Patient files may be presented before any diagnostic procedure, before initial biopsy, before primary surgery, after primary surgery, at relapse, and/or in case of a possible inclusion in a clinical trial. Patients and treatment data were prospectively included and regularly updated by the dedicated study coordinators. A monitoring of the centers activity is carried out by the three coordinating centers on a regular basis. The contribution of the different centers is presented in supplementary Table S1 (available at Annals of Oncology online).

#### The NETSARC database

The NETSARC database allows (i) to exhaustively describe the incident and prevalent population of sarcoma patients in France, by cross comparison of the pathological review database (rreps.org) and of the clinical database (netsarc.org), (ii) to monitor the diagnostic and initial treatment procedures, and (iii) to monitor patient outcome in particular survival and relapse. The database includes a limited set of data, on purpose, describing patients and tumor characteristics, surgery, relapse, and survival [12]. The center which carried out the first resection is documented, as well as potential secondary surgery, and the final quality of resection after all surgical procedures. The surgical resection system (R) from the Union Internationale contre le Cancer was chosen to define the quality of surgery, including the margins of resection. This system defines the quality of resection (R) using the surgical and pathological report: R0 = macroscopically complete resection with an absence of tumor cells in the resection margins, R1 = same, but with tumor cells visible on resection margins, and R2 = macroscopic residual disease.

Of note, 11 239 (24%) out of the 47 023 patients in the database discussed in a NETSARC MDTB had a diagnosis which was not that of a sarcoma (benign tumor, e.g. lipoma, carcinoma, lymphoma, etc.). The case was presented for discussion after the pathology review for further discussion, or before the pathology review (which was then conducted...
neurofibromatosis type 1 (NF1), p53, previous radiotherapy (RT) which are collected routinely in the NETSARC database [previous cancer, gastrointestinal stromal tumor (GIST), etc.] and (ii) also preexisting conditions for LRFS, EFS, and OS included (i) classical prognostic factors for classical prognostic factors for survival are calculated from the date of diagnosis to the date of last follow-up or death. Local relapse free survival (LRFS) is computed from the diagnostic date to the date of the last follow-up or the date of the first local recurrence. Event-free survival (EFS) was computed from the date of diagnosis to the date of the last follow-up or the date of the first local relapse, metastasis progression or death, whichever comes first.

Survival curves were plotted using a Kaplan–Meier method. Survival was compared using the log-rank test. Univariate and multivariate analysis for LRFS, EFS, and OS included (i) classical prognostic factors for sarcoma [age, gender, grade, size, site, metastasis at diagnosis, histotypes—in particular the most frequent histotypes leiomyosarcoma (LMS), LPS, undifferentiated pleomorphic sarcoma (UPS), gastrointestinal stromal tumor (GIST), etc.] and (ii) also preexisting conditions which are collected routinely in the NETSARC database [previous cancer, neurofibromatosis type 1 (NF1), p53, previous radiotherapy (RT)] [18]. It also included prognostic factors identified in univariate analysis, e.g. presentation to a NETSARC MDTB before versus after first treatment, primary and/or secondary surgery in a NETSARC center. Cox proportional hazards model was used for the multivariate analysis, introducing parameters significant (P < 0.05) in univariate analysis. Factors included in the multivariate model were identified by a backward selection procedure which entails including all the covariates in the model and removing those, whose P-value is higher than 0.10, one at a time. At each step of the model, all included variables were tested and removed if they were no longer associated with the outcome considering a 5% type I error (P-value ≥0.05). All statistical tests were two-sided. All statistical analyses were carried out using SPSS (version 22.0).

Results

Patient population

Between 1 January 2010 and 1 May 2018, 35 784 patients with sarcoma or mesenchymal tumors of intermediate malignancy were prospectively included in the NETSARC database. 29 467 (82.4%) patients were diagnosed from 1 January 2010 onward (designated as the incident population) and 6287 patients were diagnosed before, but presented to a NETSARC MDTB after 1 January 2010. The patient population studied here is that of all patients included in the database, of any age, with a histologically reviewed and confirmed soft tissue or visceral sarcoma, GIST, bone sarcomas, or tumor of intermediate malignancy in any anatomic site. Patient characteristics are presented in Table 1.

Characteristics of patients operated in NETSARC centers

Among the 29 497 incident patients, 9954 (33.7%) had a first surgery in a NETSARC center, 15 896 (54.8%) had been operated outside of a NETSARC center, 3647 (12.4%) had not been resected at last follow-up. Among those operated, the proportion operated in a NETSARC center increased from 30.4% to 42.9% from 2010 to 2017 (P < 0.001). 14 509 (49.2%) patients of the incident population were presented to a NETSARC MDTB before first treatment (Table 1), the proportion increased from 33.3% to 56.2% between 2010 and 2017.

We analyzed the characteristics of patients operated in NETSARC in the incident group (N = 29 497, since January 2010) (Table 1). Overall, the characteristics of patients operated in a NETSARC center were less favorable, with a higher proportion of patients with large tumors (P < 0.001), grade 3, retroperitoneal, UPS histology and a lower proportion of patients with tumors of intermediate malignancy (all P < 0.001). A lower proportion of sarcoma from uterus, head and neck, or internal trunk, GIST, desmoid tumors, and tumors of intermediate malignancy was observed in patients operated in NETSARC centers (Table 1).

More patients operated in NETSARC had been presented to a NETSARC MDTB (64.0% versus 41.7%, P < 0.001) before surgery, as expected. Biopsy (core or incisional) before surgery were carried out in 8585 of 15 897 (54.0%) patients operated outside NETSARC versus 8096 of 9954 (81.3%) of patients operated in NETSARC (P < 0.001). Adequate imaging before surgery had been carried out in 9378 (59.0%) versus 8239 (82.8%) of patients operated outside versus within NETSARC (P < 0.001).

Table 2 describes the predisposing conditions reported for the 35 784 patients, the number of different histological subtypes associated with these conditions. Previous cancer, previous RT, a diagnosis of NF1, and immune-depression were the most frequent predisposing condition. All others were observed in ≤0.1% of patients. Preexisting conditions were generally associated with specific predominant histological subtypes, consistently with the literature (Table 2) [1].

A previous diagnosis of cancer (12.7% versus 11.58, P = 0.03), sarcoma in an irradiated field (4.0% versus 3.0%, P < 0.001), history of Ollier’s disease (0.2% versus 0.1%, P = 0.003), and multiple exostoses (0.2% versus <0.1%, P < 0.001) were more frequently reported in patients operated in NETSARC centers. Conversely, a history of Gardner’s disease (<0.1% versus 0.1%, P = 0.02), retinoblastoma (<0.1% versus 0.1%, P = 0.02), and immunodepression (0.2% versus 0.4%, P = 0.04) were less frequently reported in patients operated in NETSARC centers reflecting probably referral patterns from organ specialists. A history of NF1 and of a Li–Fraumeni syndrome was observed at similar levels in the two groups of patients.

Quality of surgery

The quality of the surgery of operated patients was then compared between the two groups including only the 25 851 patients who had been operated of their primary tumor (87.6% of the incident patient population). Table 3 presents the rate of R0, R1, and R2 resection in NETSARC and non-NETSARC centers, at initial surgery, and after final surgery: the R0 rate in NETSARC centers was over twofold that of non-NETSARC centers, while the proportion of R2 and R unknown surgery was over twofold higher in non-NETSARC centers (Table 3, P < 0.001). The rate of reoperation was also over twofold superior in non-NETSARC centers (Table 3). Figure 1A–C presents LRFS, EFS, and OS according to the R status in all 25 851 operated patients.
Table 1. Description of the population of 35 784 patients with connective tissue tumors in Netsarc

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N = 35 784)</th>
<th>Populations (N (%) incident)</th>
<th>Operated in NETSARC (N = 9954)</th>
<th>p^a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>17 577 (49.1%)</td>
<td>14 661 (49.5%)</td>
<td>4983 (50.1%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>18 207 (50.9%)</td>
<td>14 886 (50.5%)</td>
<td>4971 (49.9%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Age at first diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (min–max)</td>
<td>60.8 (0–106)</td>
<td>55.3 (0–106)</td>
<td>53.8 (0–99)</td>
<td>0.00</td>
</tr>
<tr>
<td>&lt;18</td>
<td>1622 (4.5%)</td>
<td>1359 (4.6%)</td>
<td>522 (5.2%)</td>
<td></td>
</tr>
<tr>
<td>18–40</td>
<td>7019 (19.6%)</td>
<td>5682 (19.3%)</td>
<td>2009 (20.2%)</td>
<td></td>
</tr>
<tr>
<td>41–60</td>
<td>10 993 (30.7%)</td>
<td>8763 (29.7%)</td>
<td>3056 (30.7%)</td>
<td></td>
</tr>
<tr>
<td>61–80</td>
<td>12 599 (35.2%)</td>
<td>11 070 (37.5%)</td>
<td>3711 (37.3%)</td>
<td></td>
</tr>
<tr>
<td>&gt;80</td>
<td>2736 (7.6%)</td>
<td>2622 (8.9%)</td>
<td>656 (6.6%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>815 (2.3%)</td>
<td>1 (0.0%)</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Size of the tumor (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available in N = 11 894 (33.2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (min–max)</td>
<td>91 (1–900)</td>
<td>89.6 (1–900)</td>
<td>97.7 (1–600)</td>
<td>0.00</td>
</tr>
<tr>
<td>Primary site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft tissue</td>
<td>22 971 (64.2%)</td>
<td>19 288 (65.4%)</td>
<td>6398 (64.3%)</td>
<td></td>
</tr>
<tr>
<td>Visceral</td>
<td>5681 (19.3%)</td>
<td>1404 (14.1%)</td>
<td>1404 (14.1%)</td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>5447 (15.2%)</td>
<td>4528 (15.4%)</td>
<td>2152 (21.6%)</td>
<td></td>
</tr>
<tr>
<td>Depth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deep seated</td>
<td>23 244 (64.9%)</td>
<td>19 490 (64.3%)</td>
<td>6592 (65.2%)</td>
<td></td>
</tr>
<tr>
<td>Superficial</td>
<td>7007 (19.6%)</td>
<td>6043 (20.5%)</td>
<td>1724 (17.3%)</td>
<td></td>
</tr>
<tr>
<td>Not reported</td>
<td>5533 (15.5%)</td>
<td>4494 (15.2%)</td>
<td>1638 (16.5%)</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoma</td>
<td>29 500 (82.4%)</td>
<td>24 148 (81.9%)</td>
<td>8346 (83.8%)</td>
<td></td>
</tr>
<tr>
<td>Intermediate malignancy</td>
<td>6284 (17.6%)</td>
<td>5349 (18.1%)</td>
<td>1608 (16.2%)</td>
<td></td>
</tr>
<tr>
<td>Histological subtype (11 most frequent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>4182 (11.7%)</td>
<td>3396 (11.5%)</td>
<td>837 (8.4%)</td>
<td></td>
</tr>
<tr>
<td>UPS</td>
<td>3867 (10.8%)</td>
<td>3495 (11.8%)</td>
<td>1253 (12.6%)</td>
<td></td>
</tr>
<tr>
<td>GIST</td>
<td>2690 (7.3%)</td>
<td>2112 (7.2%)</td>
<td>637 (6.4%)</td>
<td></td>
</tr>
<tr>
<td>DDLPS</td>
<td>2277 (6.4%)</td>
<td>2114 (7.2%)</td>
<td>777 (7.8%)</td>
<td></td>
</tr>
<tr>
<td>WDLPS</td>
<td>2110 (5.9%)</td>
<td>1714 (5.8%)</td>
<td>842 (8.5%)</td>
<td></td>
</tr>
<tr>
<td>Desmoid</td>
<td>1814 (5.1%)</td>
<td>1603 (5.4%)</td>
<td>205 (2.1%)</td>
<td></td>
</tr>
<tr>
<td>Myxofibrosarcoma</td>
<td>1170 (3.3%)</td>
<td>995 (3.4%)</td>
<td>362 (3.6%)</td>
<td></td>
</tr>
<tr>
<td>Chondrosarcoma</td>
<td>1136 (3.2%)</td>
<td>901 (3.1%)</td>
<td>454 (4.6%)</td>
<td></td>
</tr>
<tr>
<td>Ewing</td>
<td>1136 (3.2%)</td>
<td>946 (3.2%)</td>
<td>360 (3.6%)</td>
<td></td>
</tr>
<tr>
<td>Angiosarcoma</td>
<td>1117 (3.1%)</td>
<td>985 (3.3%)</td>
<td>278 (2.8%)</td>
<td></td>
</tr>
<tr>
<td>Synovial</td>
<td>966 (2.7%)</td>
<td>741 (2.5%)</td>
<td>192 (2.9%)</td>
<td></td>
</tr>
<tr>
<td>Others (144 histotypes, N range 1–904)</td>
<td>13 319 (37.4%)</td>
<td>10 495 (35.6%)</td>
<td>3757 (37.7%)</td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3965 (11.1%)</td>
<td>3058 (10.4%)</td>
<td>1370 (13.8%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6165 (17.2%)</td>
<td>5053 (17.1%)</td>
<td>1910 (19.2%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>7616 (21.3%)</td>
<td>6509 (22.1%)</td>
<td>2559 (25.7%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>10 163 (28.4%)</td>
<td>8576 (29.1%)</td>
<td>2309 (23.2%)</td>
<td></td>
</tr>
<tr>
<td>Non-applicable</td>
<td>7875 (22.2%)</td>
<td>6301 (21.4%)</td>
<td>1806 (18.1%)</td>
<td></td>
</tr>
<tr>
<td>Site of the primary tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower limb</td>
<td>9342 (26.1%)</td>
<td>7805 (26.5%)</td>
<td>3693 (37.1%)</td>
<td></td>
</tr>
<tr>
<td>Thigh</td>
<td>4636 (13%)</td>
<td>3872 (13.1%)</td>
<td>1935 (19.4%)</td>
<td></td>
</tr>
<tr>
<td>Upper limb</td>
<td>3487 (9.7%)</td>
<td>2861 (9.7%)</td>
<td>977 (9.8%)</td>
<td>0.63</td>
</tr>
<tr>
<td>Trunk wall</td>
<td>5506 (15.4%)</td>
<td>4783 (16.2%)</td>
<td>1535 (15.4%)</td>
<td></td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>2945 (8.2%)</td>
<td>2278 (7.7%)</td>
<td>915 (9.2%)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>2890 (8.1%)</td>
<td>2417 (8.2%)</td>
<td>679 (6.8%)</td>
<td></td>
</tr>
<tr>
<td>Uterus</td>
<td>1733 (4.8%)</td>
<td>1357 (4.6%)</td>
<td>224 (2.3%)</td>
<td></td>
</tr>
<tr>
<td>Head and neck</td>
<td>2162 (6.0%)</td>
<td>1774 (6.0%)</td>
<td>341 (3.4%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>7719 (21.6%)</td>
<td>6622 (21.1%)</td>
<td>1610 (16.1%)</td>
<td></td>
</tr>
<tr>
<td>Metastases at diagnosis</td>
<td>No</td>
<td>27 952 (78.1%)</td>
<td>23 006 (78.0%)</td>
<td>8566 (86.1%)</td>
</tr>
</tbody>
</table>
Table 1. Continued

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N = 35 784)</th>
<th>Populations Operated in NETSARC (N = 9954)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N (%) incident</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4180 (11.6%)</td>
<td>3603 (12.2%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>3652 (10.2%)</td>
<td>2688 (9.8%)</td>
<td></td>
</tr>
<tr>
<td>N pts operated</td>
<td>31 863 (89.0%)</td>
<td>25 851 (87.6%)</td>
<td></td>
</tr>
<tr>
<td>Patients presented to NETSARC MDTB before treatment</td>
<td>NA</td>
<td>14 509 (49.2%)</td>
<td></td>
</tr>
</tbody>
</table>

*P-value comparing patients operated outside versus inside NETSARC centers.

DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; NA, Not applicable; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well differentiated liposarcoma.

Table 2. History of previous cancer or cancer predisposition

<table>
<thead>
<tr>
<th>History</th>
<th>Number of different histotypes (total N = 155)</th>
<th>Predominant histotype</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>20 540 (57.4)</td>
<td>LMS</td>
<td>2327 (11.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>7098 (19.8)</td>
<td>LMS</td>
<td>868 (12.2)</td>
</tr>
<tr>
<td>Previous cancer</td>
<td>4577 (12.2)</td>
<td>UPS</td>
<td>690 (15.1)</td>
</tr>
<tr>
<td>In irradiated field</td>
<td>1125 (3.1)</td>
<td>Angiosarcoma</td>
<td>376 (30.7)</td>
</tr>
<tr>
<td>NF1</td>
<td>288 (0.8)</td>
<td>MPNST</td>
<td>186 (64.6)</td>
</tr>
<tr>
<td>Immunodepression</td>
<td>139 (0.4)</td>
<td>Kaposis</td>
<td>64 (46.0)</td>
</tr>
<tr>
<td>Gardner</td>
<td>51 (0.1)</td>
<td>Desmoids</td>
<td>51 (100)</td>
</tr>
<tr>
<td>Multiple exostoses</td>
<td>43 (0.1)</td>
<td>Chondrosarcoma</td>
<td>38 (88.4)</td>
</tr>
<tr>
<td>Ollier</td>
<td>39 (0.1)</td>
<td>Chondrosarcoma</td>
<td>33 (81.2)</td>
</tr>
<tr>
<td>Li–Fraumeni</td>
<td>37 (0.1)</td>
<td>LMS</td>
<td>8 (21.6)</td>
</tr>
<tr>
<td>Paget disease of bone</td>
<td>20 (0.1)</td>
<td>Osteosarcoma</td>
<td>5 (25)</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>16 (0.0%)</td>
<td>LMS</td>
<td>6 (37)</td>
</tr>
<tr>
<td>Rothmund–Thomson</td>
<td>2 (0.005)</td>
<td>Osteosarcoma</td>
<td></td>
</tr>
<tr>
<td>Maffucci syndrome</td>
<td>2 (0.005)</td>
<td>Chondrosarcoma</td>
<td></td>
</tr>
<tr>
<td>NF2</td>
<td>1 (0.003)</td>
<td>GIST</td>
<td></td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>1 (0.003)</td>
<td>LPS</td>
<td></td>
</tr>
<tr>
<td>Stratiatis-Carney</td>
<td>1 (0.003)</td>
<td>GIST</td>
<td></td>
</tr>
<tr>
<td>Other*</td>
<td>2773 (7.7)</td>
<td>LMS</td>
<td>311 (11.2)</td>
</tr>
</tbody>
</table>

*No details are provided in the database.

GIST, gastrointestinal stromal tumor; LMS, leiomyosarcoma; NF1, neurofibromatosis type 1; UPS, undifferentiated pleomorphic sarcoma.

Table 3. Quality of resection in patients operated within or outside NetSARC

<table>
<thead>
<tr>
<th>First surgery outside NETSARC or no data (N = 15 897), n (%)</th>
<th>First surgery in NetSARC (N = 9954), n (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R0</td>
<td>3113 (19.6)</td>
<td>5280 (53.0)</td>
</tr>
<tr>
<td>R1</td>
<td>3208 (20.2)</td>
<td>2388 (24.0)</td>
</tr>
<tr>
<td>R2</td>
<td>1659 (8.5)</td>
<td>417 (4.2)</td>
</tr>
<tr>
<td>Unknown</td>
<td>7917 (50.0)</td>
<td>1869 (18.8)</td>
</tr>
<tr>
<td>Reoperation</td>
<td>2498 (15.7)</td>
<td>616 (6.2)</td>
</tr>
<tr>
<td>Final</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R0</td>
<td>4693 (29.5)</td>
<td>5643 (56.7)</td>
</tr>
<tr>
<td>R1</td>
<td>2492 (15.7)</td>
<td>2170 (21.8)</td>
</tr>
<tr>
<td>R2</td>
<td>981 (6.2)</td>
<td>302 (3.0)</td>
</tr>
<tr>
<td>Unknown</td>
<td>7731 (48.6)</td>
<td>1839 (18.5)</td>
</tr>
</tbody>
</table>

The bold characters are used when the P value is significant.
The absence of a documented R was associated with a higher risk of relapse and death: the R2 and R unknown groups had a similar OS indicating that the lack of information is by itself a negative predictive marker (Figure 1).

Survival

Prognostic factors for relapse and death were then evaluated in the incident population of 25,851 operated patients. Table 4
presents the prognostic factors for LRFS, EFS, and OS, with a median follow-up of 17 months. Grade, tumor site, histotype, tumor size, and age were correlated to OS, EFS, and local relapse (Table 4). Previous cancer, previous RT, and NF1 diagnosis also correlated negatively to event-free and OS. No other genetic predisposition influenced LRFS, EFS, or OS in this series.
Presentation of patients to an MDTB before initial treatment, and surgery in a NETSARC center correlated to a better LRFS, EFS, and OS, while OS was worse in this subgroup (not shown). Importantly, initial surgery in a NETSARC center was associated with a significantly improved EFS and OS (Figure 1A–F). This was observed regardless of the number of patients operated in individual NETSARC center (not shown). The OS of patients presented to a NETSARC MDTB and operated outside of NETSARC center was particularly poor (supplementary Figure S1, available at Annals of Oncology online).

In multivariate analysis, LRFS, EFS, and OS were influenced by patient related factors (gender, age), tumor presentation (site, size, location, metastases at diagnosis), histotypes, and grade. In addition, previous RT negatively correlated to LRFS. Importantly, NF1 condition was the strongest negative prognostic factor for LRFS, EFS, and OS (Table 5). Surgery in a NETSARC center was found consistently associated with a reduction in the risk of local relapse, progression, and death, with hazard ratio of 0.64, 0.83, and 0.68 for LRFS, EFS, and OS (Table 5). The favorable prognostic value of surgery in a NETSARC center was retained in addition to the presentation to a NETSARC MDTB. The later also remain an independent prognostic factor associated with a reduction in the risk of local relapse and EFS, but not OS (Table 5).

When the analysis was conducted in the same incident population of sarcoma, excluding patients with metastatic disease at diagnosis (N = 23 327), surgery in a NETSARC center remained an independent prognostic factor for LRFS, EFS, and OS (not shown). Similarly, this analysis was conducted in the entire population of 35 784 patients, pooling incident patients (N = 29 497), and patients diagnosed before 1 January 2010 (N = 6287). The latter group is of course biased with an over representation of longer survivors and of relapsing patients given the mode of entry of a presentation to an MDTB. Surgery in a NETSARC center was retained as independent favorable prognostic factors for LRFS, EFS, and OS in this exhaustive series (not shown).

### Table 5. Continued

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>1.189 (1.086–1.301)</td>
<td>0.000</td>
</tr>
<tr>
<td>UPS</td>
<td>1.133 (1.002–1.282)</td>
<td>0.048</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>1.017 (1.015–1.019)</td>
<td>0.000</td>
</tr>
<tr>
<td>Trunk wall</td>
<td>0.852 (0.728–0.951)</td>
<td>0.007</td>
</tr>
<tr>
<td>DDLPS</td>
<td>0.782 (0.667–0.916)</td>
<td>0.003</td>
</tr>
<tr>
<td>Surgery in a NETSARC center</td>
<td>0.681 (0.618–0.749)</td>
<td>0.000</td>
</tr>
<tr>
<td>Lower limb</td>
<td>0.663 (0.585–0.752)</td>
<td>0.000</td>
</tr>
<tr>
<td>Upper limb</td>
<td>0.621 (0.519–0.742)</td>
<td>0.000</td>
</tr>
<tr>
<td>LMS</td>
<td>0.615 (0.537–0.704)</td>
<td>0.000</td>
</tr>
<tr>
<td>Grade 1</td>
<td>0.431 (0.342–0.544)</td>
<td>0.000</td>
</tr>
<tr>
<td>WDLPS</td>
<td>0.385 (0.245–0.605)</td>
<td>0.000</td>
</tr>
<tr>
<td>GIST</td>
<td>0.154 (0.117–0.203)</td>
<td>0.000</td>
</tr>
<tr>
<td>Intermediate malignancy</td>
<td>0.154 (0.112–0.212)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

The bold characters are used when the P value is significant.

DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; HR, hazard ratio; LMS, leiomyosarcoma; NF1, neurofibromatosis type 1; UPS, undifferentiated pleomorphic sarcom; WDLPS, well differentiated liposarcoma.

In the present work, we investigated the impact of surgery in a reference center for sarcoma on relapse and survival in a nationwide series of 35 784 sarcoma patients seen in NETSARC MDTB since 2010. We focused on the population of incident patients diagnosed from 1 January 2010. We also analyzed the incidence and prognostic impact of preexisting conditions.


The NETSARC network aims at improving the management of sarcoma patients and their outcome nationwide. NETSARC prospectively collected all sarcoma cases reviewed in one of the 26 MDTB of the network since 1 January 2010. Centralized expert pathology review by the RREPS network is mandatory nationwide since 1 January 2010, ensuring that the diagnosis of sarcoma reported in this database is accurate. It took 3 years for NETSARC to accrue each year the number of expected incident patients. Since 2013, the number of new cases of sarcomas included in the database reached the expected incidence of these diseases in this country of 67 million inhabitants, with a 6.2/100 000/year incidence [2–4]. These numbers strongly suggest that this database gathers a close to exhaustive nationwide cohort of sarcoma patients.

In this work, we focused the survival analysis on the 29 497 incident patients with sarcoma with an initial diagnosis from 1 January 2010 to 1 May 2018. The analysis of this prospective nationwide cohort of patients indicates that the survival of sarcoma patients is improved when they are operated in a reference center. When surgery is not carried out in a reference center (N = 15 897), the rate of R0 resections is 50% lower to that of patients operated in a NETSARC center, while conversely the rate of R2 resection is more than doubled. Reoperations are carried out 2.5-fold more often in patients firstly not operated in a NETSARC center. Finally, the quality of the final surgical intervention of patients operated upfront outside NETSARC center, as evaluated by the rate of R0, R1, R2, and unknown resection, was significantly inferior even after a secondary surgery: with a lower rate of R0 resection and a higher rate of R2 resection. Importantly, this documentation of the quality of surgery was missing in a significantly higher proportion for surgeries carried out outside a NETSARC center versus NETSARC center. The lack of documentation of the R status is by itself a negative prognostic factor. When the primary surgery was done outside a NETSARC center, a secondary surgery in a NETSARC center did not allow to compensate the initial low rate of R0 surgery: the rate of inadequate surgery (R2, R unknown) surgery as final surgery remain significantly increased in the population of patients which was not initially operated in a NETSARC center.

As expected, reoperations were more frequent in patients operated outside NETSARC. We previously reported that this was an important component of the increased cost of the patient pathways for patients operated outside NETSARC [23, 24]. This study estimated a €4000 net increase of the cost of the overall procedure per patient managed outside guidelines, and it is noteworthy that over 50% of the 29 497 patients had either no previous biopsy, no...
adequate imaging, or were operated outside NETSARC. Not only these patients had a higher relapse rate and worse survival, but the excess cost of their suboptimal treatment may be estimated to 60 million euros over the study period [25, 26].

Patients operated in a NETSARC center had significantly worse prognostic characteristics as compared with those operated outside NETSARC, with larger tumors of higher grade and unfavorable locations (retroperitoneal) and histological subtypes; however, the differences in the two groups probably also reflected referral patterns of organ specialists, with a lower proportion of sarcoma from uterus, head and neck, or GIST in NETSARC centers, as well as less immunosuppressed patients and Gardner syndromes. These differences also reflected practices: for desmoid tumors, where the strategy of watchful waiting has been proposed in reference centers since a decade [27, 28], the proportion of operated patients was very low in NETSARC centers. Surgery in a NETSARC center is an independent prognostic factor for LRFS, EFS, and OS. The reduction of the risk of relapse and death is close to 35% indicating that centralization of surgery is probably the most efficient, and actually cost saving strategy to improve survival and reduce the risk of relapse and death of sarcoma patients in localized phase. Indeed, no other treatment procedure or medication is reported to enable such an increase survival of sarcoma patients to this extent, in view of the current scientific literature.

The improvement in survival observed when surgery is carried out in a NETSARC center comes in addition to the presentation to a NETSARC MDTB in the multivariate model. We had previously reported in the series of the first 12,528 patients that the presentation to a MDTB before any treatment procedure is associated with a better compliance to the clinical practice guidelines, a better quality of surgery, a better relapse free survival [12]. This later parameter is indeed associated with a better LRFS and EFS as previously described [12], but correlates to a worse OS, both in univariate and multivariate analysis. This is an intriguing observation for which we could formulate two non-mutually exclusive hypotheses: (i) presentation to a NETSARC MDTB is correlated to additional negative prognostic parameters not yet characterized and then not integrated in the multivariate model; (ii) this patient population has complex clinical characteristics requiring experienced surgical teams.

Supplementary Figure S1 (available at Annals of Oncology online) shows that patient population presented to a NETSARC MDTB but not operated in a NETSARC center is at higher risk of relapse, but represents also the population at highest risk of death, even higher than the patient population which was not presented to an MDTB and not operated in NETSARC.

Thirty-six percent of patients operated in NETSARC centers had not been presented before surgery in the MDTB. While this was observed more often in small < 3 cm tumors and visceral sites (not shown), these figures must be improved. A research program is ongoing to understand these situations.

These observations indicate that presentation to a specialized MDTB cannot be the single recommended measure, and does not constitute a sufficient organizational process for sarcoma patients, if the subsequent surgery was not carried out in a NETSARC reference center. Overall, this analysis shows that two core components, presentation to a specialized sarcoma MDTB and surgical management, must be conducted in a NETSARC center to achieve optimal tumor control and survival in sarcoma patients in this country. Presentation to a specialized MDTB, while surgery is not carried out in a reference center is actually associated with the worst survival in this series. Guidance for the treatment from reference centers to non-expert centers is not sufficient and execution of the treatment by reference centers is needed to improve patient survival. Importantly, consistent results were recently reported in other countries with different health care systems [14, 29]: management in reference centers in The Netherlands and in Spain is associated with an improved outcome. This shows that the organized management in reference center for sarcoma may be able to improve survival of sarcoma patients regardless of the health care system.

Several preexisting conditions strongly influenced the risk of relapse and survival in this nationwide study. Previous cancer, previous RT, and most importantly a history of NF1 are correlated with an increased risk of local relapse, progression, and worse survival in univariate analysis. Importantly, the two latter parameters were retained in multivariate analysis, as independent prognostic factors for local relapse (for previous RT) and for all three parameters (NF1). Actually NF1 was identified as one of the strongest adverse parameter for LRFS, EFS, and OS. This observation had not been previously reported in such a large national series and point out to explore innovative strategies, possibly specifically targeting the activated biological pathway in addition to classical treatments.

This series has several limitations: the limited follow-up, a lack of exhaustivity in the first years of network operations, and the proportion of patients with unspecified information. It is planned to expand progressively the numbers of mandatory field, which must be completed to upload the clinical case to improve the latter issue. The description of pre- and postoperative treatment is also very limited. It is important to mention that this study is not a clinical trial. A regular and systematic update of the follow-up of these patients will be important to explore patient outcome for the longer term. Nevertheless, this series is to our knowledge among the largest prospective series of sarcoma patients collected at a national level. Importantly, it is close to exhaustivity since 2013, based on the expected incidences of these tumors. These results provide a tangible confirmation of the statements proposed in clinical practice guidelines for sarcomas: treatment carried out from the initial surgical steps in reference centers offers a greater chance of disease free and OS in sarcoma. These results show that early referral, management, and treatment in reference center improve the quality of initial surgery, reduce the risk of reoperation, and improve survival to a magnitude never achieved with any new therapeutic intervention. This management may also occur at a lower overall treatment cost [23, 24]. These observations are likely to be relevant to other rare cancers, which altogether represent 20% of all cancers and often share the same management issues [30, 31]. The worse survival reported in many series is better understood based on the present results.

In conclusion, these results show that the management of patients with sarcomas must be carried out by a multidisciplinary team with experience in the management of sarcoma, from the diagnostic phase, before any treatment initiation, and for at least
the first surgical treatment. When the management is not done in reference centers, clinical practice guidelines, are less frequently applied, with an increased risk of relapse, reoperation, and death. This study also identifies NF1 as a major adverse prognostic factor increasing the risk of relapse and death to a larger magnitude than any other parameter in non-metastatic patients.

Funding

NetSARC (INCa & DGOS) and RREPS (INCa & DGOS), RESOS (INCa & DGOS) and LYRICAN (INCa-DGOS-INSERM 12563), Association DAM’s, Ensemble contre Le GIST, Eurosarc (FP7-278742), la Fondation ARC, Infosarcome, InterSARC (INCa), LabEx DEvweCAN (ANR-10-LABX-0061), Ligue de L’Ain contre le Cancer, La Ligue contre le Cancer, EURACAN (EC 739521) funded this study. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Disclosure

JYB receives research support and honoraria from Eisai, Eli Lilly, MSD, BMS, GSK, Ignyta, Novartis, Pharmamar and Roche unrelated to this work; CLP received research grants, honoraria from Roche, BMS, MSD, GSK, Novartis, Amgen; CC received grants from Pfizer, Novartis, BMS. FG received research grants from Novartis and Takeda; IRC receives research support and honoraria from Pfizer, Novartis, Takeda; ALC reports personal fees from Pharmamar, personal fees from Pfizer, personal fees from Lilly, personal fees from Novartis-GSK, personal fees from Amgen, outside the submitted work. CH, ES, PM, MJ, FG, GF, PA, RAR, FM, ADM, SC, LRLN, JG, MR, GV, OM, SC, J-CM, PG, FF, LC, FG, J-MG, FD, AM, PS, EB, CC, FD, J-PS, MR, CP, NF, CLP, J-CR, FLL, MK-P, FD, AG, MT, AI, SB, FS, OM, MB, AD, AD, DP, NP have no potential conflict of interest to disclose.

References


